Susquehanna International Group
SPRY icon

Susquehanna International Group’s ARS Pharmaceuticals SPRY Stock Holding History

Susquehanna International Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
144,300
+32,600
+29% +$312K ﹤0.01% 7492
2025
Q4 		$1.3M Sell
111,700
-173,700
-61% -$1.69M ﹤0.01% 6581
2025
Q3 		$2.87M Buy
285,400
+160,700
+129% +$2.31M ﹤0.01% 5066
2025
Q2 		$2.18M Buy
124,700
+93,000
+293% +$1.34M ﹤0.01% 5616
2025
Q1 		$399K Sell
31,700
-22,900
-42% -$276K ﹤0.01% 9404
2024
Q4 		$576K Sell
54,600
-129,500
-70% -$1.81M ﹤0.01% 8320
2024
Q3 		$2.67M Sell
184,100
-821,300
-82% -$9.77M ﹤0.01% 4757
2024
Q2 		$8.56M Buy
1,005,400
+779,800
+346% +$6.92M ﹤0.01% 2688
2024
Q1 		$2.31M Buy
225,600
+193,300
+598% +$1.44M ﹤0.01% 5014
2023
Q4 		$177K Sell
32,300
-81,000
-71% -$355K ﹤0.01% 10806
2023
Q3 		$428K Buy
+113,300
New +$744K ﹤0.01% 8586
2023
Q2 		– Sell
-208,200
Closed -$1.36M – 13075
2023
Q1 		$1.36M Buy
208,200
+13,400
+7% +$103K ﹤0.01% 6051
2022
Q4 		$1.66M Buy
194,800
+30,500
+19% +$198K ﹤0.01% 5063
2022
Q3 		$868K Buy
164,300
+38,600
+31% +$190K ﹤0.01% 7000
2022
Q2 		$533K Buy
125,700
+84,300
+204% +$294K ﹤0.01% 8108
2022
Q1 		$145K Sell
41,400
-19,600
-32% -$85.3K ﹤0.01% 11590
2021
Q4 		$406K Buy
+61,000
New +$496K ﹤0.01% 9730

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Susquehanna International Group's SPRY Position: Q1 2026 in Review

Susquehanna International Group opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 60,537 shares worth $486K. The stake represents ﹤0.01% of the portfolio and ranks #9747 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in SPRY as recently as Q2 2025.

Susquehanna International Group first reported a position in SPRY in Q2 2022 and has held it in 13 quarters since. The position peaked at $4.48M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Susquehanna International Group held 60,537 shares of ARS Pharmaceuticals worth $486K as of Q1 2026.
  • ARS Pharmaceuticals was a new Susquehanna International Group position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9747 holding.
  • Susquehanna International Group first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • Susquehanna International Group's ARS Pharmaceuticals position peaked at $4.48M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.